Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report

Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report

Radium-223 is commonly used in metastatic prostate cancer, targeting specifically bone metastases. The use of radium-223 remains, however, poorly evaluated in metastatic breast cancer. We report a case of radium-223 treatment in a 59-year-old patient with bone-only metastatic disease that progressed...

Full description

Bibliographic Details
Main Authors:	Hélène Houssiau, Francois P. Duhoux, Didier François, Emmanuel Seront
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Oncology
Subjects:	breast cancer radium-223 bone metastases chemotherapy positron emitted tomography
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.896301/full

Similar Items

Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
by: Axel Heidenreich, et al.
Published: (2019-01-01)

Еfficiacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient
by: Francesca Zacchi, et al.
Published: (2024-03-01)

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model
by: Mari I. Suominen, et al.
Published: (2023-01-01)

A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results
by: Matthew Winter, et al.
Published: (2022-08-01)

CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial
by: Rob Coleman, et al.
Published: (2020-01-01)

Radium 223 dichloride for prostate cancer treatment
by: Deshayes E, et al.
Published: (2017-09-01)

Radium-223 for the treatment of patients with castration-resistant prostate cancer with bone metastases
by: A. D. Kaprin, et al.
Published: (2018-07-01)

Feasibility study of radium-223 production in Tehran Research Reactor for treatment of bone metastases
by: Reza Bagheri, et al.
Published: (2016-02-01)

Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model
by: Mari I. Suominen, et al.
Published: (2023-08-01)

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT
by: Kalevi Kairemo, et al.
Published: (2015-10-01)

Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Yasuo Oguma, et al.
Published: (2022-09-01)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
by: Monica Vidal, et al.

Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
by: Gayed I, et al.
Published: (2018-09-01)

Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
by: Anniina Hyväkkä, et al.
Published: (2023-02-01)

Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer
by: Amanjot Sidhu, et al.
Published: (2023-08-01)

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
by: Mari I. Suominen, et al.
Published: (2021-05-01)

Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
by: Viviana Frantellizzi, et al.
Published: (2020-10-01)

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
by: Tai-Lung Cha, et al.
Published: (2017-11-01)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
by: Kim van der Zande, et al.
Published: (2021-08-01)

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment
by: Elisabet Cantó, et al.
Published: (2023-06-01)

Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer
by: Kazuya Takeda, et al.
Published: (2023-01-01)

Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
by: Weronika Gawęda, et al.
Published: (2020-10-01)

Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice
by: Raniv D. Rojo, et al.
Published: (2021-01-01)

POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Ocular complications with the use of radium-223: a case series
by: Julie R. Bloom, et al.
Published: (2022-05-01)

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
by: Masato Dobashi, et al.
Published: (2020-09-01)

Differential responses to 223Ra and Alpha-particles exposure in prostate cancer driven by mitotic catastrophe
by: Francisco D. C. Guerra Liberal, et al.
Published: (2022-07-01)

Prognostic Value of <sup>18</sup>F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223
by: Luca Filippi, et al.
Published: (2020-11-01)

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
by: Hamza Hasan, et al.
Published: (2020-06-01)

Effect of Radium-223 on the Gut Microbiota of Prostate Cancer Patients: A Pilot Case Series Study
by: Ana Fernandes, et al.
Published: (2022-10-01)

The Curies’ element: state of the art and perspectives on the use of radium in nuclear medicine
by: Sara Franchi, et al.
Published: (2023-11-01)

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer
by: Naoto T. Ueno, et al.
Published: (2020-02-01)

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis
by: Xiaohui Zeng, et al.
Published: (2022-10-01)

Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases
by: Chirayu M. Patel, et al.
Published: (2021-04-01)

Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 Dichloride
by: Kevin Kaulanjan, et al.
Published: (2022-09-01)

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerResearch in context
by: Celestia S. Higano, et al.
Published: (2023-06-01)

Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study
by: Hao Xiang Chen, et al.
Published: (2023-07-01)

Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan
by: Wei-Chun Weng, et al.
Published: (2022-10-01)